The uptake (SUVmax) of [99mTc]Tc-ADAPT6 in the liver, LDM and spleen 2 h after injection of [99mTc]Tc-ADAPT6 were 3.2 ± 1.2, 0.42 ± 0.15, 1.4 ± 0.7, respectively, in the case of HER2-positive tumours and 2.8 ± 0.6, 0.43 ± 0.2 and 1.5 ± 0.3 in the case of HER2-negative breast tumours. Here, ERBB2 is linked to neoplasm.